The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Key considerations when treating patients with CLL who have pre-existing cardiovascular disease
Matthew Davids, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, speaks about the impact of pre-existing cardiovascular disease on treatment decisions for chronic lymphocytic leukemia (CLL). He mentions the more selective BTK inhibitors, which can safely be used in this patient population, and alternative therapies, such as venetoclax-based combinations. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
